

SpineGuard reports 1H 2013 revenue up 27% to €2.3 million

PARIS and SAN FRANCISCO, July 24, 2013 – SpineGuard (FR0011464452 – ALSGD), an innovative company that designs, develops and markets disposable medical devices intended to make spine surgery safer, today announced its revenue for the first half to June 30, 2013.

€ thousands - IFRS	H1 2013	H1 2012	Δ
Revenue (June 30)	2,318	1,827	+27%

With over 3,000 procedures recorded, the Company generated sales of €2.3 million for the first half of 2013, up +27% over the same period last year. Sales increased by +30% to €1.7 million in the United States, which accounted for 49% of units sold.

Acceleration in the Company's sales expansion

In the USA, SpineGuard has been strengthening its sales organization, promoting Chuck Chester as Vice President of Sales and adding 11 distributors. Over a hundred US surgeons are now regularly using PediGuard, and 17 US spine surgery teaching institutions have adopted it in their training program.

In Russia and Mexico, SpineGuard obtained regulatory clearance from the health authorities to market the entire PediGuard range and the Cannulated PediGuard, respectively. In each of these markets that have high growth potential, the Company immediately recorded an initial order and trained sales staff and surgeons.

Pierre Jérôme, CEO and co-founder of SpineGuard, said: *"We are very pleased with the first half-year sales performance, by far the highest ever recorded. This achievement and the success of our IPO in April reinforce our vision to establish PediGuard as a standard of care for making spine surgery safer."*

Next financial press release: financial results for the 1st half of 2013, on October 17, 2013

About the PediGuard® Platform

Co-invented by Maurice Bournion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer, PediGuard is the world's first and only handheld device capable of alerting surgeons to potential pedicular or vertebral breaches. Real-time feedback is provided via audio and visual signals. Over 25,000 procedures have been performed with PediGuard on all continents. Several studies published in peer-reviewed medical and scientific journals have demonstrated that PediGuard detects 98% of pedicle breaches, presents an average screw placement accuracy of 97% (vs. 92% on average for navigation), provides 3-fold less pedicle perforations than with free-hand technique and a 3-fold reduction in neuro-monitoring alarms. It also limits radiation exposure by 25-30% and decreases by 15% the time for pedicle screw placement.

About SpineGuard®

Co-founded in 2009 by Pierre Jérôme and Stéphane Bette, former executives at Medtronic Sofamor-Danek and SpineVision, SpineGuard's primary objective is to establish its FDA-cleared and CE-marked PediGuard® device as the global standard of care for safer screw placement in spine surgery. SpineGuard's mission is to make spine surgery safer. The company has offices in San Francisco and Paris. For further information, visit www.spineguard.com.

Disclaimer

The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.

Contacts

US

Ronald Trahan, APR, Ronald Trahan Associates Inc.
+1-508-359-4005, x108

Europe

NewCap.
Investor Relations & Financial Communication
Florent Alba / Pierre Laurent
+33 (0)1 44 71 94 94

